← 產業報告目錄
VEGFR-1 Inhibitors Market Size, Share & Trends Analysis Report, By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), By Application (Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region, Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-20頁數 180報告編號 INSIGHTACE-ac5a14c06a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The global VEGFR-1 Inhibitors Market is forecasted to surge at a compound annual growth rate of 7.0% throughout the 2024–2031 forecast period.
The VEGFR-1 Inhibitors sector involves essential in treating various cancers by targeting the vascular endothelial growth factor receptor-1, which is crucial for angiogenesrepresents and tumor growth. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is supported by expanding appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, supported by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global VEGFR-1 Inhibitors Market Snapshot
Chapter 4. Global VEGFR-1 Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis
5.1. by Drug Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Type:
5.2.1. Monoclonal Antibodies
5.2.2. Tyrosine Kinase Inhibitors
5.2.3. Other Drug Types
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Renal Cell Carcinoma
6.2.2. Colorectal Cancer
6.2.3. Non-Small Cell Lung Cancer
6.2.4. Other Applications
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. VEGFR-1 Inhibitors Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
8.1.2. North America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.1.3. North America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.1.4. North America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
8.2.2. Europe VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.3. Europe VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.2.4. Europe VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
8.3.2. Asia Pacific VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.3. Asia-Pacific VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.3.4. Asia Pacific VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Latin America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
8.4.2. Latin America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.3. Latin America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.4.4. Latin America VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
8.5.2. Middle East & Africa VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.3. Middle East & Africa VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.5.4. Middle East & Africa VEGFR-1 Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. NCPC (North China Pharmaceutical Corporation)
9.2.2. Qilu Antibiotics
9.2.3. Dongying Pharmaceutical
9.2.4. Lupin Pharmaceuticals
9.2.5. SALUBRIS
9.2.6. LIVZON
9.2.7. CSPC (China Pharmaceutical Group)
9.2.8. United Laboratories
9.2.9. LKPC (Lupin Kanto Chemical)
9.2.10. HPGC (Hainan Pharmaceutical Group)
9.2.11. Shandong RuiyingEndospan
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們